Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies
Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Yifan Zhai(ASKA Pharmaceutical (Japan)), Zi Chen(Central South University), Mohammad Ahmad, James Dugan(Novant Health), Caspian Oliai(APLA Health), Joshua Richmond(Sunshine Coast University Hospital), Chong Chyn Chua(The University of Melbourne), Daniel Egan(University of Massachusetts Lowell), Maria R. Baer(University of Maryland, Baltimore), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Michael F. Leahy(Royal Perth Hospital), Zhiyan Liang(East China University of Science and Technology), Divya Mekala(Vifor Pharma (United States)), Patricia Kropf(Fox Chase Cancer Center), John Kwan(Westmead Hospital), Stephen Ting(Monash Health), Mingyu Li, Qian Niu(Kyoto University), Paul Cannell, Shaun Fleming(Peter MacCallum Cancer Centre)
Cited by 2
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655